Comments
Drug major Lupin today posted a 55.11 per cent rise in its consolidated net profit at Rs 630.04 crore for the second quarter ended September 30, driven by robust sales in the US, Japan and the domestic market.
The Mumbai-based company had posted a net profit of Rs 406.18 crore during the same period of the previous fiscal.
Net sales rose to Rs 3,116.81 crore for the second quarter, as against Rs 2,631.46 crore during the same period of the previous fiscal, the company said in a statement.
For the half-year ended September 30, the company posted a net profit of Rs 1,254.78 crore, against Rs 807.24 crore in the year-ago period, up by 55.44 per cent.
Net sales for the half year ended September 30 rose to Rs 6,400.76 crore, as compared to Rs 5,052.12 crore in the same period of the previous fiscal.
Commenting on the result, Lupin Managing Director Nilesh Gupta said: “We have had a great first-half driven by strong growth in the US, India, Japan and our API business. Our research pipeline is evolving well and we expect significant developments in the dermatology and inhalation space in the quarters to come“.
Lupin shares were trading at Rs 1,377.55 apiece on the BSE, down 1.18 per cent from its previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.